Patents by Inventor Staley Brod

Staley Brod has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11643460
    Abstract: The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject. Oral administration of ustekinumab also is useful in a method of decreasing innate inflammatory cytokines, such as Interleukin-1? and Tumor Necrosis Factor-?, Th1-like cytokines Interleukin-2 and Interferon-?, Interleukin-17 (Teff), Interleukin-12p70, and increasing Th2-like counter-regulatory cytokine Interleukin-13 in a subject.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: May 9, 2023
    Inventor: Staley Brod
  • Publication number: 20160115227
    Abstract: The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject. Oral administration of ustekinumab also is useful in a method of decreasing innate inflammatory cytokines, such as IL-1? and TNF-?, Th1-like cytokines IL-2 and IFN-?, IL-17 (Teff), IL-12p70, and increasing Th2-like counter-regulatory cytokine IL-13 in a subject.
    Type: Application
    Filed: October 28, 2014
    Publication date: April 28, 2016
    Inventor: Staley Brod
  • Patent number: 7790153
    Abstract: The present invention provides a method of treating auto-immune diseases in an animal comprising the step of orally administering a type one interferon to said animal. Also provided is a method of reducing inflammation associated with an auto-immune disease in an animal comprising the step of orally administering a type one interferon to said animal. Further provided is a method of decreasing the levels of a cytokine in an individual having multiple sclerosis, comprising the step of orally administering a type one interferon to said individual, wherein said cytokine is selected from the group consisting of TGF-?, IL-2, IL-10, IFN-? and the inflammatory soluble serum marker ICAM-1. In addition, the present invention provides a method of decreasing the incidence of insulin-dependent diabetes mellitus in at-risk populations, comprising the step of orally administering INF-? to individuals of said at-risk population.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: September 7, 2010
    Assignee: Research Development Foundation
    Inventor: Staley Brod
  • Publication number: 20070185030
    Abstract: The present invention provides methods of treating multiple sclerosis, type 1 diabetes mellitus and other autoimmune diseases by administering a soluble immune response suppressor (SIRS) peptide or a variant thereof to an individual having such disease. The SIRS peptide or variant reduces the severity of or frequency of relapse of multiple sclerosis and reduces the inflammation associated with multiple sclerosis and other autoimmune diseases.
    Type: Application
    Filed: June 9, 2005
    Publication date: August 9, 2007
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventor: Staley Brod
  • Publication number: 20040151694
    Abstract: The present invention provides a method of treating auto-immune diseases in an animal comprising the step of orally administering a type one interferon to said animal. Also provided is a method of reducing inflammation associated with an auto-immune disease in an animal comprising the step of orally administering a type one interferon to said animal. Further provided is a method of decreasing the levels of a cytokine in an individual having multiple sclerosis, comprising the step of orally administering a type one interferon to said individual, wherein said cytokine is selected from the group consisting of TGF-&bgr;, IL-2, IL-10, IF-&ggr; and the inflammatory soluble serum marker ICAM-1. In addition, the present invention provides a method of decreasing the incidence of insulin-dependent diabetes mellitus in at-risk populations, comprising the step of orally administering INF-&agr; to individuals of said at-risk population.
    Type: Application
    Filed: March 16, 2004
    Publication date: August 5, 2004
    Inventor: Staley Brod